title: Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
abstract: Three recent studies have reported that fibrin in solution significantly inhibits the ability of heparin to catalyze the inhibition of thrombin by antithrombin III. In addition, heparin inhibits the release of fibrinopeptide A by clot-bound thrombin less effectively than it inhibits the release of fibrinopeptide A by thrombin in solution. We have also reported that dermatan sulfate, which catalyzes thrombin inhibition by heparin cofactor II, inhibits thrombus growth in rabbits more effectively than heparin. Because the results of these studies suggest that fibrin inhibits the reactivity of thrombin with antithrombin III-heparin but not with heparin cofactor II-dermatan sulfate, we compared the relative catalytic effects of heparin and dermatan sulfate on thrombin inhibition in plasma, both in the presence and absence of fibrin. We quantitated the rates of thrombin inhibition by antithrombin III and heparin cofactor II by specific enzyme-linked immunosorbent assays. When it was generated, fibrin was kept in solution by adding 2 mmol/L Gly-Pro-Arg-Pro to plasma. Fibrinogen-fibrin reduced the reactivity of thrombin with plasma antithrombin III, both in the presence of and in the absence of heparin. In contrast, the catalytic action of dermatan sulfate on thrombin inhibition by plasma heparin cofactor II was unimpaired by fibrinogen-fibrin. Based on the ability of dermatan sulfate to inhibit thrombus growth in rabbits, failure of fibrinogen-fibrin to moderate the catalytic action of dermatan sulfate may account for its greater antithrombotic effectiveness relative to that of heparin.
authors.affiliation: Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
authors.forename: J I
authors.initials: JI
authors.lastname: Okwusidi
authors.forename: N
authors.initials: N
authors.lastname: Anvari
authors.forename: M
authors.initials: M
authors.lastname: Kulczycky
authors.forename: M A
authors.initials: MA
authors.lastname: Blajchman
authors.forename: M R
authors.initials: MR
authors.lastname: Buchanan
authors.forename: F A
authors.initials: FA
authors.lastname: Ofosu
mesh_terms: D000990:Antithrombin III / Q000494:pharmacology; D003871:Dermatan Sulfate / Q000494:pharmacology*; D005337:Fibrin / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D015844:Heparin Cofactor II / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D013917:Thrombin / Q000037:antagonists & inhibitors*
chemical_list: D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D000990:Antithrombin III; D005337:Fibrin; D006493:Heparin; D013917:Thrombin